Glial-Neuronal Interaction in Synapses: A Possible Mechanism of the Pathophysiology of Bipolar Disorder.
Astrocytes
Bipolar disorder
Glial cells
Microglia
Neurons
Tripartite synapses
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
25
3
2023
Statut:
ppublish
Résumé
Bipolar disorder (BD) is a severe and chronic psychiatric disorder that affects approximately 1-4% of the world population and is characterized by recurrent episodes of mania or hypomania and depression. BD is also associated with illnesses marked by immune activation, such as metabolic syndrome, obesity, type 2 diabetes mellitus, and cardiovascular diseases. Indeed, a connection has been suggested between neuroinflammation and peripheral inflammatory markers in the pathophysiology of BD, which can be associated with the modulation of many dysfunctional processes, including synaptic plasticity, neurotransmission, neurogenesis, neuronal survival, apoptosis, and even cognitive/behavioral functioning. Rising evidence suggests that synaptic dysregulations, especially glutamatergic system dysfunction, are directly involved in mood disorders. It is becoming clear that dysregulations in connection and structural changes of glial cells play a central role in the BD pathophysiology. This book chapter highlighted the latest findings that support the theory of synaptic dysfunction in BD, providing an overview of the alterations in neurotransmitters release, astrocytic uptake, and receptor signaling, as well as the role of inflammation on glial cells in mood disorders. Particular emphasis is given to the alterations in presynaptic and postsynaptic neurons and glial cells, all cellular elements of the "tripartite synapse," compromising the neurotransmitters system, excitatory-inhibitory balance, and neurotrophic states of local networks in mood disorders. Together, these studies provide a foundation of knowledge about the exact role of the glial-neuronal interaction in mood disorders.
Identifiants
pubmed: 36949311
doi: 10.1007/978-981-19-7376-5_9
doi:
Substances chimiques
Neurotransmitter Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-208Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
Références
Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561–72.
pubmed: 26388529
doi: 10.1016/S0140-6736(15)00241-X
Severus E, Bauer M. Bipolar disorders in DSM-5. Nervenarzt. 2014;85(5):543–7.
pubmed: 24796943
doi: 10.1007/s00115-013-3987-1
Panchal P, Kaltenboeck A, Harmer CJ. Cognitive emotional processing across mood disorders. CNS Spectr. 2019;24(1):54–63.
pubmed: 30644352
doi: 10.1017/S109285291800130X
Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand. 2016;134(2):91–103.
pubmed: 27097559
doi: 10.1111/acps.12581
Martinez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007;9(1-2):103–13.
pubmed: 17391354
doi: 10.1111/j.1399-5618.2007.00327.x
Petersen JZ, Porter RJ, Miskowiak KW. Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. J Affect Disord. 2019;246:763–74.
pubmed: 30623822
doi: 10.1016/j.jad.2018.12.105
Martino DJ, Strejilevich SA, Scapola M, Igoa A, Marengo E, Ais ED, et al. Heterogeneity in cognitive functioning among patients with bipolar disorder. J Affect Disord. 2008;109(1-2):149–56.
pubmed: 18234352
doi: 10.1016/j.jad.2007.12.232
Godin O, Etain B, Henry C, Bougerol T, Courtet P, Mayliss L, et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry. 2014;75(10):1078–85; quiz 85.
pubmed: 25373115
doi: 10.4088/JCP.14m09038
Jerrell JM, McIntyre RS, Tripathi A. A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry. 2010;71(11):1518–25.
pubmed: 20584522
doi: 10.4088/JCP.09m05585ora
Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17.
pubmed: 20934453
doi: 10.1016/j.neubiorev.2010.10.001
Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47(9):1119–33.
pubmed: 23768870
doi: 10.1016/j.jpsychires.2013.05.018
Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709.
pubmed: 26903267
pmcid: 6056174
doi: 10.1038/mp.2016.3
Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.
pubmed: 19497250
doi: 10.4088/JCP.08r04505
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15–25.
pubmed: 23419545
doi: 10.1016/j.biopsych.2013.01.007
Guloksuz S, Altinbas K, Aktas Cetin E, Kenis G, Bilgic Gazioglu S, Deniz G, et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord. 2012;143(1-3):148–52.
pubmed: 22749155
doi: 10.1016/j.jad.2012.04.044
Hoseth EZ, Ueland T, Dieset I, Birnbaum R, Shin JH, Kleinman JE, et al. A study of TNF pathway activation in schizophrenia and bipolar disorder in plasma and brain tissue. Schizophr Bull. 2017;43(4):881–90.
pubmed: 28049760
pmcid: 5515106
Khairova RA, Machado-Vieira R, Du J, Manji HK. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2009;12(4):561–78.
pubmed: 19224657
doi: 10.1017/S1461145709009924
Panaccione I, Spalletta G, Sani G. Neuroinflammation and excitatory symptoms in bipolar disorder. Neuroimmunol Neuroinflamm. 2015;2:215–27.
doi: 10.4103/2347-8659.167304
Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res. 2013;145(1-3):36–42.
pubmed: 23403415
doi: 10.1016/j.schres.2012.12.023
Patel JP, Frey BN. Disruption in the blood-brain barrier: the missing link between brain and body inflammation in bipolar disorder? Neural Plast. 2015;2015:708306.
pubmed: 26075104
pmcid: 4444594
doi: 10.1155/2015/708306
Hauwel M, Furon E, Canova C, Griffiths M, Neal J, Gasque P. Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, “protective” glial stem cells and stromal ependymal cells. Brain Res Brain Res Rev. 2005;48(2):220–33.
pubmed: 15850661
doi: 10.1016/j.brainresrev.2004.12.012
Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol. 2009;513(5):532–41.
pubmed: 19226510
doi: 10.1002/cne.21974
Herculano-Houzel S. The glia/neuron ratio: how it varies uniformly across brain structures and species and what that means for brain physiology and evolution. Glia. 2014;62(9):1377–91.
pubmed: 24807023
doi: 10.1002/glia.22683
Boche D, Perry VH, Nicoll JA. Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol. 2013;39(1):3–18.
pubmed: 23252647
doi: 10.1111/nan.12011
Brisch R, Wojtylak S, Saniotis A, Steiner J, Gos T, Kumaratilake J, et al. The role of microglia in neuropsychiatric disorders and suicide. Eur Arch Psychiatry Clin Neurosci. 2021;272(6):929–45.
pubmed: 34595576
pmcid: 9388452
doi: 10.1007/s00406-021-01334-z
Nakagawa Y, Chiba K. Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases. Pharmaceuticals. 2014;7(12):1028–48.
pubmed: 25429645
pmcid: 4276905
doi: 10.3390/ph7121028
Franco R, Fernandez-Suarez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 2015;131:65–86.
pubmed: 26067058
doi: 10.1016/j.pneurobio.2015.05.003
Herzog C, Pons Garcia L, Keatinge M, Greenald D, Moritz C, Peri F, et al. Rapid clearance of cellular debris by microglia limits secondary neuronal cell death after brain injury in vivo. Development. 2019;146(9):174698.
doi: 10.1242/dev.174698
Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288–95.
pubmed: 18567623
doi: 10.1093/brain/awn109
Gomes-Leal W. Microglial physiopathology: how to explain the dual role of microglia after acute neural disorders? Brain Behav. 2012;2(3):345–56.
pubmed: 22741103
pmcid: 3381634
doi: 10.1002/brb3.51
Kalafatakis I, Karagogeos D. Oligodendrocytes and microglia: key players in myelin development, damage and repair. Biomol Ther. 2021;11(7):1058.
Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.
pubmed: 24228900
pmcid: 3846682
doi: 10.1186/1741-7015-11-200
Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75–83.
pubmed: 28338954
doi: 10.1093/schbul/sbx035
Rahimian R, Wakid M, O’Leary LA, Mechawar N. The emerging tale of microglia in psychiatric disorders. Neurosci Biobehav Rev. 2021;131:1–29.
pubmed: 34536460
doi: 10.1016/j.neubiorev.2021.09.023
Torres-Sanchez S, Perez-Caballero L, Berrocoso E. Cellular and molecular mechanisms triggered by deep brain stimulation in depression: a preclinical and clinical approach. Prog Neuro-psychopharmacol Biol Psychiatry. 2017;73:1–10.
doi: 10.1016/j.pnpbp.2016.09.005
Qiu L, Ye J, Ji F, Li G, Li G, Ma X, et al. Common and distinct global functional connectivity density alterations in patients with bipolar disorder with and without auditory verbal hallucination during major depressive episodes. Brain Imaging Behav. 2020;14(6):2724–30.
pubmed: 31900890
doi: 10.1007/s11682-019-00222-4
Haarman BC, Burger H, Doorduin J, Renken RJ, Sibeijn-Kuiper AJ, Marsman JB, et al. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder - a combined magnetic resonance imaging and positron emission tomography study. Brain Behav Immun. 2016;56:21–33.
pubmed: 26348581
doi: 10.1016/j.bbi.2015.09.004
Pandey GN. Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain. Mod Trends Pharmacopsychiatry. 2017;31:79–95.
pubmed: 28738369
doi: 10.1159/000470809
Pantazatos SP, Huang YY, Rosoklija GB, Dwork AJ, Arango V, Mann JJ. Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity. Mol Psychiatry. 2017;22(5):760–73.
pubmed: 27528462
doi: 10.1038/mp.2016.130
Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology. 2018;95:43–9.
pubmed: 29800779
pmcid: 6427066
doi: 10.1016/j.psyneuen.2018.05.026
Mechawar N, Savitz J. Neuropathology of mood disorders: do we see the stigmata of inflammation? Transl Psychiatry. 2016;6(11):e946.
pubmed: 27824355
pmcid: 5314124
doi: 10.1038/tp.2016.212
Efremova L, Chovancova P, Adam M, Gutbier S, Schildknecht S, Leist M. Switching from astrocytic neuroprotection to neurodegeneration by cytokine stimulation. Arch Toxicol. 2017;91(1):231–46.
pubmed: 27052459
doi: 10.1007/s00204-016-1702-2
Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007;101(5):1205–13.
pubmed: 17403030
pmcid: 1949347
doi: 10.1111/j.1471-4159.2007.04487.x
Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, Mueller K. Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol. 2010;2010:780645.
pubmed: 20585358
pmcid: 2878670
doi: 10.1155/2010/780645
Anderson G, Maes M. Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr Psychiatry Rep. 2015;17(2):8.
pubmed: 25620790
doi: 10.1007/s11920-014-0541-1
Buspavanich P, Adli M, Himmerich H, Berger M, Busche M, Schlattmann P, et al. Faster speed of onset of the depressive episode is associated with lower cytokine serum levels (IL-2, -4, -6, -10, TNF-alpha and IFN-gamma) in patients with major depression. J Psychiatr Res. 2021;141:287–92.
pubmed: 34271459
doi: 10.1016/j.jpsychires.2021.06.033
Lindqvist D, Dhabhar FS, James SJ, Hough CM, Jain FA, Bersani FS, et al. Oxidative stress, inflammation and treatment response in major depression. Psychoneuroendocrinology. 2017;76:197–205.
pubmed: 27960139
doi: 10.1016/j.psyneuen.2016.11.031
Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol. 2015;40:134–41.
pubmed: 25773161
doi: 10.1016/j.semcdb.2015.03.002
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465–77.
pubmed: 22678511
pmcid: 3681811
doi: 10.1038/nrn3257
Ramirez LA, Perez-Padilla EA, Garcia-Oscos F, Salgado H, Atzori M, Pineda JC. A new theory of depression based on the serotonin/kynurenine relationship and the hypothalamicpituitary-adrenal axis. Biomedica. 2018;38(3):437–50.
pubmed: 30335249
Savitz J, Dantzer R, Wurfel BE, Victor TA, Ford BN, Bodurka J, et al. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology. 2015;52:200–11.
pubmed: 25486577
doi: 10.1016/j.psyneuen.2014.11.015
Liu H, Ding L, Zhang H, Mellor D, Wu H, Zhao D, et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder. Front Psych. 2018;9:552.
doi: 10.3389/fpsyt.2018.00552
Benevenuto D, Saxena K, Fries GR, Valvassori SS, Kahlon R, Saxena J, et al. Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: a preliminary study. Bipolar Disord. 2021;23(7):689–96.
pubmed: 33098737
doi: 10.1111/bdi.13027
Mahmoud S, Gharagozloo M, Simard C, Gris D. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cell. 2019;8(2):184.
doi: 10.3390/cells8020184
Giovannoni F, Quintana FJ. The role of astrocytes in CNS inflammation. Trends Immunol. 2020;41(9):805–19.
pubmed: 32800705
pmcid: 8284746
doi: 10.1016/j.it.2020.07.007
Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A. 1994;91(22):10625–9.
pubmed: 7938003
pmcid: 45074
doi: 10.1073/pnas.91.22.10625
Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL, et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci. 1998;20(4-5):291–9.
pubmed: 9778565
doi: 10.1159/000017324
Diaz-Ruiz A, Salgado-Ceballos H, Montes S, Maldonado V, Tristan L, Alcaraz-Zubeldia M, et al. Acute alterations of glutamate, glutamine, GABA, and other amino acids after spinal cord contusion in rats. Neurochem Res. 2007;32(1):57–63.
pubmed: 17160506
doi: 10.1007/s11064-006-9225-5
Colombo E, Farina C. Astrocytes: key regulators of neuroinflammation. Trends Immunol. 2016;37(9):608–20.
pubmed: 27443914
doi: 10.1016/j.it.2016.06.006
Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–74.
pubmed: 25975510
pmcid: 4559283
doi: 10.1016/j.tins.2015.04.003
Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384–92.
pubmed: 19488045
doi: 10.1038/mp.2009.47
Feresten AH, Barakauskas V, Ypsilanti A, Barr AM, Beasley CL. Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophr Res. 2013;150(1):252–7.
pubmed: 23911257
doi: 10.1016/j.schres.2013.07.024
Ferensztajn-Rochowiak E, Tarnowski M, Samochowiec J, Michalak M, Ratajczak MZ, Rybakowski JK. Increased mRNA expression of peripheral glial cell markers in bipolar disorder: the effect of long-term lithium treatment. Eur Neuropsychopharmacol. 2016;26(9):1516–21.
pubmed: 27474686
doi: 10.1016/j.euroneuro.2016.07.009
Vadodaria KC, Mendes APD, Mei A, Racha V, Erikson G, Shokhirev MN, et al. Altered neuronal support and inflammatory response in bipolar disorder patient-derived astrocytes. Stem Cell Rep. 2021;16(4):825–35.
doi: 10.1016/j.stemcr.2021.02.004
Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, et al. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. Eur Neuropsychopharmacol. 2002;12(3):269–72.
pubmed: 12007679
doi: 10.1016/S0924-977X(02)00029-9
Dong XH, Zhen XC. Glial pathology in bipolar disorder: potential therapeutic implications. CNS Neurosci Therap. 2015;21(5):393–7.
doi: 10.1111/cns.12390
Keshavarz M. Glial cells as key elements in the pathophysiology and treatment of bipolar disorder. Acta Neuropsychiatrica. 2017;29(3):140–52.
pubmed: 27772534
doi: 10.1017/neu.2016.56
Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95(22):13290–5.
pubmed: 9789081
pmcid: 23786
doi: 10.1073/pnas.95.22.13290
Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology. 2005;178(2-3):161–6.
pubmed: 15316717
doi: 10.1007/s00213-004-1999-z
Van Eldik LJ, Wainwright MS. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci. 2003;21(3-4):97–108.
pubmed: 14530573
Liu Y, Zhao J, Guo W. Emotional roles of mono-aminergic neurotransmitters in major depressive disorder and anxiety disorders. Front Psychol. 2018;9:2201.
pubmed: 30524332
pmcid: 6262356
doi: 10.3389/fpsyg.2018.02201
Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 1996;29(1):2–11.
pubmed: 8852528
doi: 10.1055/s-2007-979535
Kasa K, Otsuki S, Yamamoto M, Sato M, Kuroda H, Ogawa N. Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry. 1982;17(8):877–83.
pubmed: 7115838
Peabody CA, Faull KF, King RJ, Whiteford HA, Barchas JD, Berger PA. CSF amine metabolites and depression. Psychiatry Res. 1987;21(1):1–7.
pubmed: 2440071
doi: 10.1016/0165-1781(87)90056-4
Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS. CSF amine metabolites in depression. Biol Psychiatry. 1992;31(2):112–8.
pubmed: 1371076
doi: 10.1016/0006-3223(92)90198-9
Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry. 1994;35(2):121–7.
pubmed: 7513191
doi: 10.1016/0006-3223(94)91201-7
Palsson E, Sellgren C, Ryden E, Kizza R, Pelanis A, Zetterberg H, et al. Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. J Neural Transm. 2017;124(9):1135–43.
pubmed: 28656371
doi: 10.1007/s00702-017-1746-3
Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, et al. A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry. 2016;21(10):1342–50.
pubmed: 26666201
doi: 10.1038/mp.2015.186
Redmond DE, Katz MM, Maas JW, Swann A, Casper R, Davis JM. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry. 1986;43(10):938–47.
pubmed: 2428328
doi: 10.1001/archpsyc.1986.01800100028005
Swann AC, Secunda S, Davis JM, Robins E, Hanin I, Koslow SH, et al. CSF monoamine metabolites in mania. Am J Psychiatry. 1983;140(4):396–400.
pubmed: 6188381
doi: 10.1176/ajp.140.4.396
Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today. 2019;24(2):606–15.
pubmed: 30447328
doi: 10.1016/j.drudis.2018.11.007
Fee C, Banasr M, Sibille E. Somatostatin-positive gamma-aminobutyric acid interneuron deficits in depression: cortical microcircuit and therapeutic perspectives. Biol Psychiatry. 2017;82(8):549–59.
pubmed: 28697889
pmcid: 5610074
doi: 10.1016/j.biopsych.2017.05.024
Scotti-Muzzi E, Chile T, Moreno R, Pastorello BF, da Costa LC, Henning A, et al. ACC Glu/GABA ratio is decreased in euthymic bipolar disorder I patients: possible in vivo neurometabolite explanation for mood stabilization. Eur Arch Psychiatry Clin Neurosci. 2021;271(3):537–47.
pubmed: 31993746
doi: 10.1007/s00406-020-01096-0
Brady RO Jr, McCarthy JM, Prescot AP, Jensen JE, Cooper AJ, Cohen BM, et al. Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord. 2013;15(4):434–9.
pubmed: 23634979
pmcid: 5504910
doi: 10.1111/bdi.12074
Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102(1):75–90.
pubmed: 30946828
pmcid: 6450409
doi: 10.1016/j.neuron.2019.03.013
Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383–406.
pubmed: 21079608
doi: 10.1038/mp.2010.120
Nery FG, Tallman MJ, Cecil KM, Blom TJ, Patino LR, Adler CM, et al. N-acetylcysteine for depression and glutamate changes in the left prefrontal cortex in adolescents and young adults at risk for bipolar disorder: a pilot study. Early Interv Psychiatry. 2022;16(2):195–9.
pubmed: 33797205
doi: 10.1111/eip.13149
Smaragdi A, Chavez S, Lobaugh NJ, Meyer JH, Kolla NJ. Differential levels of prefrontal cortex glutamate+glutamine in adults with antisocial personality disorder and bipolar disorder: a proton magnetic resonance spectroscopy study. Prog Neuro-psychopharmacol Biol Psychiatry. 2019;93:250–5.
doi: 10.1016/j.pnpbp.2019.04.002
Weis S, Llenos IC, Dulay JR, Verma N, Sabunciyan S, Yolken RH. Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J Neural Transm. 2007;114(2):261–71.
pubmed: 16897601
doi: 10.1007/s00702-006-0544-0
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.
pubmed: 10686270
doi: 10.1016/S0006-3223(99)00230-9
Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, et al. Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. J Clin Psychiatry. 2017;78(8):1068–74.
pubmed: 27929610
pmcid: 5641476
doi: 10.4088/JCP.15m10440
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802.
pubmed: 20679587
pmcid: 3000408
doi: 10.1001/archgenpsychiatry.2010.90
Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–46.
pubmed: 22297150
pmcid: 3343177
doi: 10.1016/j.biopsych.2011.12.010
Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Pract. 2017;21(2):99–103.
pubmed: 28271731
doi: 10.1080/13651501.2017.1297834
Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, Rybakowski JK. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. 2015;48(2):78–9.
pubmed: 25347227
Bahji A, Pierce M, Wong J, Roberge JN, Ortega I, Patten S. Comparative efficacy and acceptability of psychotherapies for self-harm and suicidal behavior among children and adolescents: a systematic review and network meta-analysis. JAMA Netw Open. 2021;4(4):e216614.
pubmed: 33861328
pmcid: 8052594
doi: 10.1001/jamanetworkopen.2021.6614
Wilkowska A, Szalach L, Cubala WJ. Ketamine in bipolar disorder: a review. Neuropsychiatr Dis Treat. 2020;16:2707–17.
pubmed: 33209026
pmcid: 7670087
doi: 10.2147/NDT.S282208
Araque A, Parpura V, Sanzgiri RP, Haydon PG. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 1999;22(5):208–15.
pubmed: 10322493
doi: 10.1016/S0166-2236(98)01349-6
Farhy-Tselnicker I, Allen NJ. Astrocytes, neurons, synapses: a tripartite view on cortical circuit development. Neural Dev. 2018;13(1):7.
pubmed: 29712572
pmcid: 5928581
doi: 10.1186/s13064-018-0104-y
Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev. 2006;86(3):1009–31.
pubmed: 16816144
doi: 10.1152/physrev.00049.2005
Kettenmann H, Verkhratsky A. Neuroglia–living nerve glue. Fortschr Neurol Psychiatr. 2011;79(10):588–97.
pubmed: 21989511
doi: 10.1055/s-0031-1281704
Lynch MA. The multifaceted profile of activated microglia. Mol Neurobiol. 2009;40(2):139–56.
pubmed: 19629762
doi: 10.1007/s12035-009-8077-9
Gomes C, Ferreira R, George J, Sanches R, Rodrigues DI, Goncalves N, et al. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A2A receptor-dependent manner: A2A receptor blockade prevents BDNF release and proliferation of microglia. J Neuroinflammation. 2013;10:16.
pubmed: 23363775
pmcid: 3567964
doi: 10.1186/1742-2094-10-16
Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR 3rd, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155(7):1596–609.
pubmed: 24360280
pmcid: 4033691
doi: 10.1016/j.cell.2013.11.030
Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A. 2012;109(4):197–205.
doi: 10.1073/pnas.1111098109
Rebola N, Simoes AP, Canas PM, Tome AR, Andrade GM, Barry CE, et al. Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem. 2011;117(1):100–11.
pubmed: 21235574
doi: 10.1111/j.1471-4159.2011.07178.x
Schafer DP, Lehrman EK, Stevens B. The “quad-partite” synapse: microglia-synapse interactions in the developing and mature CNS. Glia. 2013;61(1):24–36.
pubmed: 22829357
doi: 10.1002/glia.22389
Scianni M, Antonilli L, Chece G, Cristalli G, Di Castro MA, Limatola C, et al. Fractalkine (CX3CL1) enhances hippocampal N-methyl-D-aspartate receptor (NMDAR) function via D-serine and adenosine receptor type A2 (A2AR) activity. J Neuroinflammation. 2013;10:108.
pubmed: 23981568
pmcid: 3765929
doi: 10.1186/1742-2094-10-108
Lingamaneni R, Birch ML, Hemmings HC. Widespread inhibition of sodium channel-dependent glutamate release from isolated nerve terminals by isoflurane and propofol. Anesthesiology. 2001;95(6):1460–6.
pubmed: 11748406
doi: 10.1097/00000542-200112000-00027
Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, et al. Glial cells in (patho)physiology. J Neurochem. 2012;121(1):4–27.
pubmed: 22251135
pmcid: 3304021
doi: 10.1111/j.1471-4159.2012.07664.x
Lauriat TL, McInnes LA. EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders. Mol Psychiatry. 2007;12(12):1065–78.
pubmed: 17684493
doi: 10.1038/sj.mp.4002065
Jia YF, Choi Y, Ayers-Ringler JR, Biernacka JM, Geske JR, Lindberg DR, et al. Differential SLC1A2 promoter methylation in bipolar disorder with or without addiction. Front Cell Neurosci. 2017;11:217.
pubmed: 28785205
pmcid: 5520464
doi: 10.3389/fncel.2017.00217
Poletti S, Locatelli C, Radaelli D, Lorenzi C, Smeraldi E, Colombo C, et al. Effect of early stress on hippocampal gray matter is influenced by a functional polymorphism in EAAT2 in bipolar disorder. Prog Neuro-psychopharmacol Biol Psychiatry. 2014;51:146–52.
doi: 10.1016/j.pnpbp.2014.01.021
Castillo M, Kwock L, Courvoisie H, Hooper SR. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am J Neuroradiol. 2000;21(5):832–8.
pubmed: 10815657
pmcid: 7976743
Cecil KM, DelBello MP, Morey R, Strakowski SM. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord. 2002;4(6):357–65.
pubmed: 12519095
doi: 10.1034/j.1399-5618.2002.02235.x
Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61(5):450–8.
pubmed: 15123489
doi: 10.1001/archpsyc.61.5.450
Kubo H, Nakataki M, Sumitani S, Iga JI, Numata S, Kameoka N, et al. 1H-magnetic resonance spectroscopy study of glutamate-related abnormality in bipolar disorder. J Affect Disord. 2017;208:139–44.
pubmed: 27770643
doi: 10.1016/j.jad.2016.08.046
Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718–26.
pubmed: 18602089
pmcid: 2577764
doi: 10.1016/j.biopsych.2008.05.014
Eastwood SL, Harrison PJ. Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2008;33(4):933–45.
pubmed: 17507910
doi: 10.1038/sj.npp.1301457
Eastwood SL, Harrison PJ. Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry. 2010;67(11):1010–6.
pubmed: 20079890
pmcid: 2868790
doi: 10.1016/j.biopsych.2009.12.004
Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord. 2009;11(7):711–25.
pubmed: 19839996
doi: 10.1111/j.1399-5618.2009.00752.x
Fatemi SH, Folsom TD, Thuras PD. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011;128(1-3):37–43.
pubmed: 21303731
pmcid: 3085603
doi: 10.1016/j.schres.2010.12.025
Scarr E, Gray L, Keriakous D, Robinson PJ, Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord. 2006;8(2):133–43.
pubmed: 16542183
doi: 10.1111/j.1399-5618.2006.00300.x
Kim HJ, Thayer SA. Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides. Mol Pharmacol. 2009;75(5):1021–30.
pubmed: 19188338
pmcid: 2672813
doi: 10.1124/mol.108.052357
Khayachi A, Ase A, Liao C, Kamesh A, Kuhlmann N, Schorova L, et al. Chronic lithium treatment alters the excitatory/inhibitory balance of synaptic networks and reduces mGluR5-PKC signalling in mouse cortical neurons. J Psychiatry Neurosci. 2021;46(3):E402–E14.
pubmed: 34077150
pmcid: 8327978
doi: 10.1503/jpn.200185
Zhang Y, Wu S, Xie L, Yu S, Zhang L, Liu C, et al. Ketamine within clinically effective range inhibits glutamate transmission from astrocytes to neurons and disrupts synchronization of astrocytic SICs. Front Cell Neurosci. 2019;13:240.
pubmed: 31244607
pmcid: 6581012
doi: 10.3389/fncel.2019.00240
Lazarevic V, Yang Y, Flais I, Svenningsson P. Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors. Mol Psychiatry. 2021;26(12):7425–35.
pubmed: 34376822
pmcid: 8872981
doi: 10.1038/s41380-021-01246-3
Muller HK, Wegener G, Liebenberg N, Zarate CA Jr, Popoli M, Elfving B. Ketamine regulates the presynaptic release machinery in the hippocampus. J Psychiatr Res. 2013;47(7):892–9.
pubmed: 23548331
pmcid: 3678963
doi: 10.1016/j.jpsychires.2013.03.008
Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry. 2001;50(6):395–406.
pubmed: 11566156
doi: 10.1016/S0006-3223(01)01084-8
Brauch RA, Adnan El-Masri M, Parker JC Jr, El-Mallakh RS. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J Affect Disord. 2006;91(1):87–90.
pubmed: 16469390
doi: 10.1016/j.jad.2005.08.015
Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry. 2003;53(12):1086–98.
pubmed: 12814860
doi: 10.1016/S0006-3223(03)00114-8
Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry. 2001;49(9):741–52.
pubmed: 11331082
doi: 10.1016/S0006-3223(01)01080-0
Sakai T, Oshima A, Nozaki Y, Ida I, Haga C, Akiyama H, et al. Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology. 2008;28(2):143–50.
pubmed: 18069969
doi: 10.1111/j.1440-1789.2007.00867.x
Fatemi SH, Earle JA, McMenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry. 2000;5(6):654–63, 571.
pubmed: 11126396
doi: 10.1038/sj.mp.4000783
Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57(11):1061–9.
pubmed: 11074872
doi: 10.1001/archpsyc.57.11.1061
Tobe BTD, Crain AM, Winquist AM, Calabrese B, Makihara H, Zhao WN, et al. Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci U S A. 2017;114(22):E4462–E71.
pubmed: 28500272
pmcid: 5465887
doi: 10.1073/pnas.1700111114
Pantazopoulos H, Wiseman JT, Markota M, Ehrenfeld L, Berretta S. Decreased numbers of somatostatin-expressing neurons in the amygdala of subjects with bipolar disorder or schizophrenia: relationship to circadian rhythms. Biol Psychiatry. 2017;81(6):536–47.
pubmed: 27259817
doi: 10.1016/j.biopsych.2016.04.006
Steullet P, Cabungcal JH, Bukhari SA, Ardelt MI, Pantazopoulos H, Hamati F, et al. The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress. Mol Psychiatry. 2018;23(10):2057–65.
pubmed: 29180672
doi: 10.1038/mp.2017.230
Wang AY, Lohmann KM, Yang CK, Zimmerman EI, Pantazopoulos H, Herring N, et al. Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathol. 2011;122(5):615–26.
pubmed: 21968533
pmcid: 4207060
doi: 10.1007/s00401-011-0881-4
Ishii T, Ishikawa M, Fujimori K, Maeda T, Kushima I, Arioka Y, et al. In vitro modeling of the bipolar disorder and schizophrenia using patient-derived induced pluripotent stem cells with copy number variations of PCDH15 and RELN. eNeuro. 2019;6(5):403.
doi: 10.1523/ENEURO.0403-18.2019
Kim KH, Liu J, Sells Galvin RJ, Dage JL, Egeland JA, Smith RC, et al. Transcriptomic analysis of induced pluripotent stem cells derived from patients with bipolar disorder from an old order amish pedigree. PLoS One. 2015;10(11):e0142693.
pubmed: 26554713
pmcid: 4640865
doi: 10.1371/journal.pone.0142693
Mitterauer BJ. Balancing and imbalancing effects of astrocytic receptors in tripartite synapses. Common pathophysiological model of mental disorders and epilepsy. Med Hypotheses. 2015;84(4):315–20.
pubmed: 25655220
doi: 10.1016/j.mehy.2015.01.025